KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Short term Debt (2017 - 2026)

Biocryst Pharmaceuticals filings provide 7 years of Short term Debt readings, the most recent being $38.5 million for Q4 2025.

  • On a quarterly basis, Short term Debt rose 17.69% to $38.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $38.5 million, a 17.69% increase, with the full-year FY2025 number at $38.5 million, up 17.69% from a year prior.
  • Short term Debt hit $38.5 million in Q4 2025 for Biocryst Pharmaceuticals, up from $37.7 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $38.5 million in Q4 2025 to a low of $23.6 million in Q4 2023.
  • Median Short term Debt over the past 3 years was $33.0 million (2024), compared with a mean of $32.3 million.
  • Biggest five-year swings in Short term Debt: surged 38.66% in 2024 and later rose 14.2% in 2025.
  • Biocryst Pharmaceuticals' Short term Debt stood at $23.6 million in 2023, then surged by 38.66% to $32.7 million in 2024, then increased by 17.69% to $38.5 million in 2025.
  • The last three reported values for Short term Debt were $38.5 million (Q4 2025), $37.7 million (Q3 2025), and $35.7 million (Q2 2025) per Business Quant data.